# Progress Note 06 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Alan Turing (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML007-SYN
- Date: 2026-10-06
- Fictional facility: St. Posthumous Health Center
- Fictional author: Rupert Hallam, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Six-month review of gynecomastia and depression in continuation treatment. **S**

## History of present illness

Mr. Turing returns about six months after his first visit. His right ankle sprain from August healed within three weeks and he is back to about 40 km a week. He has finished the course of 16 psychotherapy sessions and now sees the psychologist monthly. He feels like himself, sleeps about seven hours, and has been changing at his running club again for a month. He takes bupropion XL 150 mg and cholecalciferol every morning, has missed no doses, and has no side effects. The breast tissue is no longer tender, though he can still feel a small disc on the left. He has had no suicidal thoughts. **S**

| Element | Detail |
|---|---|
| Interval change | Feels like himself; back with his running club |
| Ankle | Sprain healed within three weeks |
| Psychotherapy | Course of 16 sessions finished; monthly sessions now |
| Breasts | No tenderness; small disc on the left |
| Safety | No suicidal thoughts |
| PHQ-9 | 4 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Breast | Negative | No tenderness or discharge |
| Genitourinary | Negative | Libido and erections normal |
| Musculoskeletal | Negative | Ankle recovered |
| Psychiatric | Negative | Mood good; no suicidal thoughts, elevated mood, or racing thoughts |

4 systems reviewed. **S**

## Current medications

- Cholecalciferol 1,000 units (25 mcg) oral tablet, one tablet by mouth daily **S**
- Bupropion extended-release 150 mg oral tablet, one tablet by mouth each morning **S**

## Allergies

- No known allergy **S**

## Objective

BP 118/72 mmHg; pulse 54 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 68.6 kg; BMI 21.7 kg/m². All vital signs are synthetic.

PHQ-9: 4; GAD-7: 3; Total testosterone: 536 ng/dL; Estradiol: 24 pg/mL; 25-hydroxyvitamin D: 38 ng/mL. All results are synthetic.

## Change since baseline

- PHQ-9: 15 at baseline, 4 at this visit **S**
- GAD-7: 8 at baseline, 3 at this visit **S**
- Total testosterone: 112 ng/dL (low) at baseline, 536 ng/dL at this visit **S**
- Estradiol: 148 pg/mL (high) at baseline, 24 pg/mL at this visit **S**
- 25-hydroxyvitamin D: 22 ng/mL (low) at baseline, 38 ng/mL at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well, lean, and cheerful |
| Breast | Examined with his agreement: a soft, non-tender disc of glandular tissue about 2 cm behind the left nipple and 1 cm behind the right; no discrete mass, skin change, discharge, or nodes |
| Mental status | Alert; mood "good"; affect full and reactive; thought process linear; no suicidal ideation; insight and judgment good |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Residual gynecomastia, improving** (N62). Small and non-tender six months after the estrogen stopped. Testosterone 536 ng/dL and estradiol 24 pg/mL are normal. **S**
   - Watchful waiting to about twelve months after the estrogen stopped; if the tissue persists and he wants it removed, a plastic surgery opinion, because long-standing gynecomastia becomes fibrous and seldom regresses.
2. **Vitamin D insufficiency, resolved** (E55.9). 25-hydroxyvitamin D 38 ng/mL on cholecalciferol 1,000 units. **S**
   - Continue cholecalciferol 1,000 units daily through the winter.
3. **Major depressive disorder, single episode, in remission** (F32.1). PHQ-9 4: remission about six months after starting psychotherapy and four months after adding bupropion. Suicide risk remains low, with protective factors stronger than at intake. **S**
   - Continue bupropion XL 150 mg for at least six months after remission, then decide together about tapering.
   - Monthly psychotherapy; PHQ-9 every two to three months.
   - Collaborative safety plan reviewed and unchanged; 988 Suicide & Crisis Lifeline and the clinic number confirmed.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Breast examination for size, tenderness, and any discrete mass | Every visit until the gynecomastia settles | Completed today | A soft, non-tender disc about 2 cm on the left and 1 cm on the right; no discrete mass |
| Laboratory | Testosterone and estradiol at six months | Once, to confirm sustained recovery | Completed today | Testosterone 536 ng/dL and estradiol 24 pg/mL, normal |
| Laboratory | 25-hydroxyvitamin D on replacement | About three to six months after starting | Completed today | 38 ng/mL, up from 22 |
| Referral | Surgical opinion for persistent gynecomastia | If it persists about twelve months and troubles him | Due | Not yet: six months since the estrogen stopped and still shrinking |
| Survey | PHQ-9 | Baseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuation | Completed today | 4: remission |
| Survey | Monthly PHQ-9 between the sixteen-week review and today | At least monthly during acute treatment | Deferred | Not done, a deviation from the protocol: no interim PHQ-9 was scheduled after the response at sixteen weeks, although remission had not been reached, leaving nine weeks unmeasured. No harm resulted judging by today's review: he reached remission and had no suicidal thoughts, and he saw the psychologist throughout. Corrective action: the clinic registry now books a monthly PHQ-9 call until a remission score is recorded |
| Survey | GAD-7 | With the PHQ-9 when anxiety symptoms were present at baseline | Completed today | 3 |
| Survey | Suicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9) | Every visit during active treatment | Completed today | No suicidal thoughts, intent, plan, or behavior since the last visit; PHQ-9 item 9 scored 0. Protective factors stronger than at intake. Safety plan reviewed |
| Medication safety | Adherence, adverse effects, and blood pressure on bupropion | Every visit during active treatment | Completed today | No missed doses; no side effects; blood pressure 118/72 mmHg |
| Self-management | Psychotherapy, sleep, running, and social contact | Every visit during active treatment | Completed today | Course of 16 sessions finished, monthly now; sleep about seven hours; running 40 km a week with his club |
| Laboratory | Lithium, anticonvulsant, or antipsychotic monitoring (levels, metabolic tests, AIMS) | Only on those drugs | Not indicated | Not on any of these drugs |

## Goal progress

- Testosterone, LH, and FSH back in the reference range within six months of the last estrogen dose, without testosterone therapy. Outcome by 2026-08-04: Testosterone 452 ng/dL with normal LH and FSH at sixteen weeks. **S**
- Breast tenderness gone and gynecomastia reduced; a surgical opinion offered if it persists and troubles him. Outcome by 2026-10-06: Tenderness gone by six months; small residual glandular tissue; watchful waiting to twelve months. **S**
- Depression response (PHQ-9 down by at least 50 percent) by sixteen weeks, then remission (PHQ-9 below 5). Outcome by 2026-10-06: PHQ-9 7 at sixteen weeks (down 53 percent) and 4 at six months. **S**
- Back to running about 40 km a week and changing at his club again. Outcome by 2026-10-06: Running 40 km a week and back with the club by six months. **S**

## Guideline basis

- EAA clinical practice guidelines: gynecomastia evaluation and management (2019), European Academy of Andrology
- Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline (2018), Endocrine Society
- Osteoporosis in Men: An Endocrine Society Clinical Practice Guideline (2012), Endocrine Society
- VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022), United States Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge

## Follow-up

- Preventive visit in two weeks; depression review with PHQ-9 in about two months. **S**
- Next scheduled visit 2026-10-20: periodic adult preventive visit. **S**
